Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Have you been diagnosed with breast cancer with brain metastases? If so, you may be able to take part in a research study looking at the safety of giving a new drug called olaparib concurrently (at the same time) with stereotactic radiosurgery, followed by immunotherapy and chemotherapy, to patients with breast cancer with brain metastases.

Are you suspected of having or have been diagnosed with ovarian cancer? if so, you may be able to participate in a research study looking at creating personalized stem cells from the skin of ovarian cancer patients to see if these stem cells can attack cancer cells. This work may be able to help us find more treatment options for ovarian cancer patients in the future.

Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.

Have you been diagnosed with metastatic brain cancer (tumor)? If so, you may be able to take part in a research study looking at the safety of giving radiation therapy through a device called GammaTiles™ to patients with newly diagnosed metastatic brain tumors planned for surgical resection.

Have you been diagnosed with Leukemia? You may be able to take part in a research study to find out if a new study drug can help put your blood cancer into remission.

Are you a patient with locally advanced or metastatic squamous cell carcinoma? If so, you may be eligible to participate in a clinical research study involving an investigational drug, NBTXR3.

Can we increase the clinical complete response rate (tumor disappears by exam, endoscopy, and imaging) by adding a 3rd drug (irinotecan) to the standard regimen of FOLFOX or CAPOX given following long-course chemoradiation for patients with locally advanced rectal cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your rectal cancer. The usual approach is defined as care most people get for locally advanced rectal cancer.

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.

Have you been diagnosed with multiple myeloma that has not responded to treatment or has come back after treatment? If so, you may be able to take part in a research study looking at the safety and efficacy of giving a new drug called ABBV-383 to patients with relapsed/refractory multiple myeloma.